I agree it is not a dichotomous argument; both magnetic resonance imaging (MRI) and patient report are important in assessing disease activity in the multiple sclerosis (MS) patient. They are complementary tools for the neurologist. MRI is overwhelmingly important in three aspects (1) as a diagnostic tool; (2) in assessing prognosis in the clinically isolated syndrome (CIS) or early relapsing-remitting MS (RRMS) patient; (3) in assessing responsiveness to therapy. Patient report measures are important in assessing mood disorders and the multiple dimensions of illness impact. They reflect the patient's view of the the effect of the disease and therapies used, within their own personal and social context. Patient report measures are used increasingly in clinical trials, often as secondary or tertiary endpoints and their use is advocated by regulatory authorities. A discussion of generic and MS-specific instruments and their use in pivotal trials is well summarised in a recent review. 1
The problem of response shift
One of the problems with patient report measures in longitudinal studies is response shift. An instrument may show significant improvements in health related quality of life in response to a therapy over a relatively short period of time. 2 However, over the longer term even with deteriorating disability, a process of re-evaluation, coping and adapation to the disease process takes place. The patient may thus redefine the target construct, the quality of life measure, and scores which might have been expected to worsen, improve. This can regarded of course as a very healthy process; expectations change, realistic goals are set and psychological well-being predominates over increased physical disability. This phenomenon is recognised in other patent groups with metastatic disease, 3 stroke 4 and other progressive neurological disease 5 . In a study of the responsiveness of the Multiple Sclerosis Impact Scale-29 (MSIS-29) 6 we found evidence of response shift in patients with stable but significant disability over time; scores improved although physician measures had not changed. 7 As physicians we welcome that as evidence of the psychological robustness of our patients. We still use the MSIS-29 in the clinic as well as the Beck's Depression Inventory, because they are invaluable tools in assessing the physical and the psychological aspects of MS that are important to patients. Using these tools patients tell us indirectly about their illness, much more than directly to the (male?) doctor at the clinic interview.
Similarly, the routine MRI has significant limitations, too numerous to mention now, but alluded to in a previous commentary. 8 Certainly, if neurologists were shown a number of patients' MRI scans with a range of MS pathology of varying severity, the correlation between their assessment of how disabled the patients might be and the patients' actual disabilities would be very poor. As a surrogate measure the MRI is fine in the early phase of disease assessment, but when the going gets tough, bring in patient report measures.
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